Surgery remains a critical treatment option for GISTs, especially if compared to other rare and aggressive cancers like mesothelioma (which shares a common PI3K/AKT/mTOR activation pathway) where surgery has no or a limited impact on survival rates, even if applied in the early stages of the disease [17]. This evidence concerns the gene MTOR and mesothelioma.